ImmunoGen Inc. [NASDAQ: IMGN] traded at a high on 01/14/21, posting a 3.69 gain after which it closed the day’ session at $7.58. The company report on January 5, 2021 that ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 91,800 shares of its common stock to two new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The results of the trading session contributed to over 6152450 shares changing hands. Over the past one week, the price volatility of ImmunoGen Inc. stands at 4.41% while the volatility over the past one month is 5.15%.
The market cap for IMGN stock reached $1.49 billion, with 194.71 million shares outstanding and 176.17 million shares in the current float. Compared to the average trading volume of 2.56M shares, IMGN reached a trading volume of 6152450 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ImmunoGen Inc. [IMGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMGN shares is $9.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMGN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for ImmunoGen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 26, 2020. The new note on the price target was released on October 02, 2020, representing the official price target for ImmunoGen Inc. stock. On December 17, 2019, analysts increased their price target for IMGN shares from 5 to 9.
The Average True Range (ATR) for ImmunoGen Inc. is set at 0.38, with the Price to Sales ratio for IMGN stock in the period of the last 12 months amounting to 16.33.
How has IMGN stock performed recently?
ImmunoGen Inc. [IMGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.37. With this latest performance, IMGN shares gained by 4.41% in over the last four-week period, additionally plugging by 68.07% over the last 6 months – not to mention a rise of 53.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMGN stock in for the last two-week period is set at 66.22, with the RSI for the last a single of trading hit 70.80, and the three-weeks RSI is set at 64.23 for ImmunoGen Inc. [IMGN]. The present Moving Average for the last 50 days of trading for this stock 6.39, while it was recorded at 7.15 for the last single week of trading, and 4.81 for the last 200 days.
ImmunoGen Inc. [IMGN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ImmunoGen Inc. [IMGN] shares currently have an operating margin of -85.98. ImmunoGen Inc.’s Net Margin is presently recorded at -126.57.
Return on Total Capital for IMGN is now -60.07, given the latest momentum, and Return on Invested Capital for the company is -125.91. Additionally, IMGN Total Debt to Total Capital is recorded at 202.50, with Total Debt to Total Assets ending up at 63.92.
Reflecting on the efficiency of the workforce at the company, ImmunoGen Inc. [IMGN] managed to generate an average of -$1,388,440 per employee. Receivables Turnover for the company is 4.19 with a Total Asset Turnover recorded at a value of 0.31.ImmunoGen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
Earnings analysis for ImmunoGen Inc. [IMGN]
With the latest financial reports released by the company, ImmunoGen Inc. posted 0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 160.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMGN.
Insider trade positions for ImmunoGen Inc. [IMGN]
There are presently around $1,077 million, or 73.60% of IMGN stock, in the hands of institutional investors. The top three institutional holders of IMGN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 23,080,128, which is approximately -0.993% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 14,188,530 shares of the stock with an approximate value of $107.55 million in IMGN stocks shares; and BLACKROCK INC., currently with $104.1 million in IMGN stock with ownership of nearly -4.918% of the company’s market capitalization.
Positions in ImmunoGen Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 74 institutional holders increased their position in ImmunoGen Inc. [NASDAQ:IMGN] by around 19,597,729 shares. Additionally, 98 investors decreased positions by around 16,061,913 shares, while 40 investors held positions by with 106,419,893 shares. The mentioned changes placed institutional holdings at 142,079,535 shares, according to the latest SEC report filing. IMGN stock had 25 new institutional investments in for a total of 8,492,405 shares, while 29 institutional investors sold positions of 3,298,451 shares during the same period.